(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced positive results from the Phase III evERA study evaluating investigational giredestrant in combination with everolimus in people with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with a cyclin-dependent kinase 4/6 inhibitor and endocrine therapy. The study met both co-primary endpoints, showing a statistically significant and clinically meaningful improvement in progression-free survival in both the intention-to-treat and ESR1-mutated populations, compared with standard-of-care endocrine therapy plus everolimus.
Levi Garraway, chief medical officer and head of Global Product Development, said: "We look forward to discussing these results with regulatory authorities with the goal of making this giredestrant-based regimen available to many people with advanced ER-positive breast cancer."
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
